Hola,
Are you new here?

SECRETE-HF

financed

SECRETED FACTORS IN CARDIAC REMODELING PROVOKE TUMORIGENESIS AND END ORGAN DAMAG...

SECRETED FACTORS IN CARDIAC REMODELING PROVOKE TUMORIGENESIS AND END ORGAN DAMAGE IN HEART FAILURE The objective of SECRETE-HF is to demonstrate the effects of secreted factors from failing hearts to explain the etiology of multimorbidity in heart failure (HF). The project focuses on two co-morbid patterns: 1) the emerging susc... see more

31/03/2025

ERASMUS MC

2M€

Project Budget: 2M€

Project leader

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDA... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

PARTICIPATION DEPralty Sin fecha límite de participación.

Ver 3 Participantes

Financing granted El organismo H2020 notifico la concesión del proyecto The day 2025-03-31

ERC-2018-COG: ERC Consolidator Grant Scope:Objectives

I+D

Cerrada does 7 years

0% 100% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

ERASMUS MC

432.75K€ | Leader

STEREOCARTO S.L.

359.94K€ | participant

UNIVERSITAIR MEDISCH CENTRUM...

1.57M€ | participant

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 72 months Date Start: 2019-03-19
End date: 2025-03-31

Project leader

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDA... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Project Budget 2M€

participation deadline Sin fecha límite de participación.

Project description The objective of SECRETE-HF is to demonstrate the effects of secreted factors from failing hearts to explain the etiology of multimorbidity in heart failure (HF). The project focuses on two co-morbid patterns: 1) the emerging susceptibility of HF patients for incident cancer, 2) the more established co-morbid conditions of renal, liver and pulmonary disease in HF. The rationale is: • HF treatment has improved, yet morbidity and mortality remain high, which can be attributed to co-morbid conditions rather than pump failure alone. • HF treatment is heart-oriented, neglecting the systemic effects that come with HF, and the associated morbidity and mortality. • Using innovative experimental approaches such as organ transplant models, target finding, and deep phenotyping of clinical databases I will dissect HF-derived effects on tumor growth and organ damage. OBJECTIVES 1. To establish the effects of HF, due to different etiologies, using the state-of-the-art heart transplantation murine model with (spontaneous) formation of colon and renal tumors, and phenotype tumor growth, as well as the main HF-affected organs: kidney, liver and lungs. 2. Identification of the cardiac secretome using unbiased approaches. 3. Integrate the results and identify overlapping and diverse factors from different HF forms, and their consequences for tumor growth and kidney/liver/lung remodeling. 4. Validate discoveries in human cohorts with data on incident HF, cancer and organ function. 5. Create clinical algorithms to detect, monitor and act on extra-cardiac disease. WORKPACKAGES WP 1: Create HF, murine heart transplantation models; phenotype tumor growth and organ involvement. WP 2: Explore the proteomic, metabolomic and extracellular vesicle profiles from HF subforms. WP 3: Validate secreted factors in vitro and in vivo. WP 4: Validate human relevance in large population-based cohorts with unique phenotyping. WP 5: Describe added value of novel markers and design clinical

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers